Pipeline

Pipeline Overview

We are assembling a robust portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematologic malignancies. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses.
Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator
CNTY-101 READ MORE CLOSE

CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma
CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. IND submission is targeted mid 2022.

iNK
CD19
B-Cell Malignancies
Mid 2022

CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma
CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. IND submission is targeted mid 2022.

CNTY-103 READ MORE CLOSE

CNTY-103: Our CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma
CNTY-103 represents our first clinical product candidate targeting a solid tumor. We believe targeting two antigen targets will help address tumor heterogeneity and antigen loss in GBM. We believe the clinical safety profile of engineered iNK cells may be optimal in GBM.

iNK
CD133 + EGFR
Glioblastoma
2024

CNTY-103: Our CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma
CNTY-103 represents our first clinical product candidate targeting a solid tumor. We believe targeting two antigen targets will help address tumor heterogeneity and antigen loss in GBM. We believe the clinical safety profile of engineered iNK cells may be optimal in GBM.

CNTY-102 READ MORE CLOSE

CNTY-102: Our CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies
CNTY-102 will simultaneously target CD19 and CD79b and is designed to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability while targeting CD79b, an independently regulated, ubiquitous and validated B-cell target.

iT
CD19 + CD79b
B-Cell Malignancies
2024

CNTY-102: Our CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies
CNTY-102 will simultaneously target CD19 and CD79b and is designed to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability while targeting CD79b, an independently regulated, ubiquitous and validated B-cell target.

CNTY-104 READ MORE CLOSE

CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia
Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.

iT or iNK
Multi-specific
Acute Myeloid Leukemia
2024

CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia
Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.

CNTY-106 READ MORE CLOSE

CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma
Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.

iT or iNK
Multi-specific
Multiple Myeloma
2024

CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma
Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.

     TBD      READ MORE CLOSE
iT or iNK
TBD
Solid Tumors
TBD
     TBD      READ MORE CLOSE
iNK
TBD
Hematological Malignancies
2023

Solid Tumors

Hematologic Tumors